New technologies toward dendritic cell-based cancer immunotherapies.
Immunologically naive T cells are activated most efficiently or even exclusively by special subsets of antigen presenting cells, termed dendritic cells (DC). Members of the DC family have been identified in virtually all epithelial tissues that are constantly exposed to environmental antigens or infectious microbes. For example, skin is equipped with at least two members of this family, epidermal Langerhans cells (LC) and dermal DC. DC have been shown to play pathogenic roles in several different inflammatory/immunological disorders and protective roles against infectious pathogenes and cancer development. In this review article, we will overview the recent progress in the development of DC-based immunotherapies for the prevention and treatment of cancers.
Matsue
H
H
Department of Dermatology, University of Texas, Southwestern Medical Center, Dallas 75235-9069, USA.
Morita
A
A
Matsue
K
K
Takashima
A
A
D000818:Animals; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007801:Langerhans Cells / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy
D019496:Cancer Vaccines